

Conference on Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture

Keiichi Iwata – President, Sumitomo Chemical Co., Ltd.
Toru Kimura – President, Sumitomo Pharma Co., Ltd.

December 17, 2024



Change and Innovation

~ with the **Power** of Chemistry ~

Long-term vision and positioning of each business sector

Innovative Solution Provider

~A company that solves social issues with innovative technology~



Food

Achieve regenerative

Agro & Life Solutions



ICT

Innovate IT

ICT & Mobility Solutions



Healthcare

Spread leading-edge medicine

Advanced Medical Solutions



Environment

Reduce environmental impact

Essential & Green Materials



positioning

Growth drivers

Leading short-term growth with a focus on crop protection products and semiconductor materials

New growth areas

Cultivating as the third pillar to take off after 2030

Core domains

Transitioning to a solution business primarily based on technology licensing

Full entry into the regenerative medicine & cell therapies business

Regenerative medicine & cell therapies business

Market

- The global market for cell therapies was estimated to be worth approximately **\$2.0 billion** as of 2022.
- It is expected to continue growing at an annual rate of **10% to 15%** in the coming years.

Advantage

Sumitomo Pharma

- The technologies and advanced knowledge acquired through their activities as a front runner in regenerative medicine and cell therapy
- ◆ **Developing the world's first iPS cell-derived cell therapy (Parkinson's disease)**
- ◆ **October 2021: Approval of RETHYMIC® (with approximately 40 procedures already performed) (pediatric congenital athymia)**



SUMITOMO CHEMICAL

- Development support based on expertise in industrial engineering, analysis and evaluation, and quality management
- Resources at the Environmental Health Science Laboratory and the Bioscience Research Laboratory

The entire Sumitomo Chemical Group is promoting development and business expansion.

We aim for a business scale of over **350[※] billion yen** by the late 2030s


※ The estimation of the business value assumes that the multiple products that are under development will be successfully launched and does not make any adjustment based on probability of success

The long-term goals of the Advanced Medical Solutions Sector

Advanced Medical Solutions Sector

Long-term portfolio (Approximation of revenues)

Grow topline through
organic growth +
M&A



Regenerative medicine & cell therapies business

Regenerative medicine & cell therapies

CDMO
(regenerative medicine & cell therapies)

Sale of the RI diagnostic reagent business (Nihon Medi-Physics)

After reconsidering from the perspective of the best owner, we decided to sell to GE Healthcare.

We aim to achieve the 2035 sales target of 300 billion yen without the RI diagnostic reagent business.

(From the Management Strategy Briefing Materials on April 30, 2024.
The estimation of the regenerative medicine & cell therapies business makes adjustments based on the probability of success.)

Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.